Skip to main content

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Trial Status: Active

Background: A glioblastoma is a tumor in the brain. It is treated with surgery, chemotherapy and radiation therapy. However, most people s tumors come back after therapy. When the tumor grows back, surgery or chemotherapy may not be possible or may no longer work. Repeat radiation therapy or re-irradiation, is an option for treating these tumors when they regrow. Objective: To find out the safety and highest tolerated dose of re-irradiation for people who have recurrent glioblastoma. Eligibility: People ages 18 50 who have glioblastoma that has been treated with radiation but has regrown. Design: Participants will be screened with: Medical history Physical exam MRI of the brain: They will lie in a machine that takes pictures of the brain. Participants will have baseline tests before they start therapy. These will include: Blood tests Neuropsychological tests: These test things like memory, attention, and thinking. Quality of life questionnaire Eye and hearing tests Participants will get a CT of the brain prior to radiation start in order to plan the radiation treatment. Once the plan is completed, they will receive radiation once a day Monday Friday for a total of 10 17 treatments. They will lie on their back for about 10 minutes while they get the treatment. Participants will be monitored for side effects. After they finish treatment, participants will have visits 1, 2, and 3 months later. Then they will have them every 2 months for 3 years. These will include: Medical history Physical exam Blood tests MRI of the brain. Quality of life questionnaire Neuropsychological tests (at some visits) After 3 years, participants will be contacted by phone each month.

Inclusion Criteria

  • - INCLUSION CRITERIA: 1. Histological diagnosis Previous histologic diagnosis of glioblastoma, transformation to glioblastoma or gliosarcoma established by biopsy or resection prior to enrollment as evident on NIH or outside pathology. 2. Patients must be age greater than or equal to 18. 3. Patients should have a KPS greater than or equal to 70% 4. Prior standard radiation therapy to a dose ranging from 50 to 60 Gy at 1.8 to 2 Gy per fraction. 5. Patients must be more than or equal to 14 days from previous cytotoxic treatment. 6. Concurrent therapy The concurrent use of bevacizumab is allowed if previously initiated for tumor progression or symptomatic management. Prior temozolomide or other cytotoxic chemotherapy is allowed. 7. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. 8. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. EXCLUSION CRITERIA: 1. Prior therapy < than 2 weeks since surgical re-resection or biopsy 2. Pregnant or breast feeding females are excluded due to potential mutagenic effects on the developing fetus or newborn 3. Preexisting grade 3 or 4 nervous system disorder as per CTCAE Version 4.0 4. Clinically significant unrelated systemic illness (including but not limited to active life threatening infection, cardiac or neurologic events, current hospital admission for a coexisting comorbid illness), which would make it impossible for the patient to tolerate re-irradiation or systemic chemotherapy or likely to interfere with the results. 5. Patients exhibiting baseline grade 3 or 4 by CTCAE criteria are excluded due to difficulty in assigning these to the study intervention as treatment related DLT. 6. Patients with preexisting known or suspected radiation sensitivity syndromes will be excluded due to potential confounding effect on outcome.


National Institutes of Health Clinical Center
Status: ACTIVE
Contact: National Cancer Institute Referral Office
Phone: 888-624-1937


- Although the survival of gliomas has improved, most high grade gliomas will recur in

field or adjacent to the treatment field within months to years of the original

treatment. In newly diagnosed GBM, the concurrent use of radiation and temozolomide is

standard of care.

- Surgical resection upon recurrence is possible in less than 50% of patients. For a

significant proportion of recurrent glioma patients in whom reresection is not

favourable and for whom systemic options have been exhausted, re-irradiation has emerged

as a possible treatment option.

- Using modern precision RT techniques (stereotactic radiosurgery (SRS), stereotactic

radiotherapy (SRT) or intensity modulated radiation therapy (IMRT), Rapid Arc

techniques), re-irradiation has proven a feasible option with possible benefit in

outcome as these techniques are often able to minimize dose to previously treated organs

at risk in the field (OAR) and treat the recurrence safely.

- Data from multiple retrospective studies has indicated that not only is re-irradiation

feasible, but it may actually improve survival in the appropriately selected patient.


The primary objective of this phase I study is to determine maximum tolerated re-irradiation

dose (MTD).


- Recurrent glioblastoma or gliosarcoma

- Prior standard radiation therapy to a dose ranging from 50 to 60 Gy at 1.8 to 2 Gy per


- Prior irradiation > 12 months from enrollment on protocol.

- Age greater than or equal to 18.

- KPS greater than or equal to 70


- Radiation therapy will be administered daily Monday-Friday at Radiation Oncology Branch

(ROB), NCI. All the protocol related follow-up appointments will occur at NCI ROB.

Radiation therapy dose will be administered on consecutive treatment days, 5 fractions

per week via a linear accelerator using 6 MV photons or greater. Using a 3 plus 3 design

, and three dose escalation levels, with 6 patients per dose level with 9 total patients

at the MTD (provided no DLT), a maximum of 21 evaluable patients will be enrolled.

- Time to progression will be determined by the interval from initiation of treatment on

protocol to progression as per RANO criteria.

- Neurologic decline without radiographic evidence of tumor will be designated as

treatment related toxicity. Survival duration will be determined by the interval from

initiation of treatment on protocol to date of death.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
National Cancer Institute

Principal Investigator
Kevin Camphausen

  • Primary ID 160081
  • Secondary IDs NCI-2018-03323, 16-C-0081, NCI-2016-00394
  • ID NCT02709226